Xie, T.; Dickson, K.-A.; Yee, C.; Ma, Y.; Ford, C.E.; Bowden, N.A.; Marsh, D.J.
Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. Cancers 2022, 14, 4621.
https://doi.org/10.3390/cancers14194621
AMA Style
Xie T, Dickson K-A, Yee C, Ma Y, Ford CE, Bowden NA, Marsh DJ.
Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. Cancers. 2022; 14(19):4621.
https://doi.org/10.3390/cancers14194621
Chicago/Turabian Style
Xie, Tao, Kristie-Ann Dickson, Christine Yee, Yue Ma, Caroline E. Ford, Nikola A. Bowden, and Deborah J. Marsh.
2022. "Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival" Cancers 14, no. 19: 4621.
https://doi.org/10.3390/cancers14194621
APA Style
Xie, T., Dickson, K. -A., Yee, C., Ma, Y., Ford, C. E., Bowden, N. A., & Marsh, D. J.
(2022). Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. Cancers, 14(19), 4621.
https://doi.org/10.3390/cancers14194621